Integra enhances lower extremity offering with Metasurg buy
This article was originally published in Clinica
Executive Summary
Integra Lifesciences has announced the purchase of Metasurg, a specialist in foot and ankle orthopedic products, which it completed in December. As well as bolstering Integra’s lower extremity offering, the deal also gives it the opportunity to distribute Metasurg’s BioFix regenerative product “as a possible complement to Integra's wound care product offering.” BioFix, which is derived from human placental tissue, provides a wound covering and tissue matrix for surgical wounds and tissue defects. Houston, Texas-based Metasurg was founded in 2005, and brought in revenues of around $6m in 2013, representing double-digit growth over the prior year, according to Integra, which “expects minimal impact on profits in 2015 and slower growth during the transition period, before returning to double digit growth longer term.” Clinica recorded one other acquisition by Integra in 2014, of Medtronic's MicroFrance and Xomed manual ENT and laparascopy instrumentation lines.